Literature DB >> 29524273

Major prognostic factors for recurrence and survival independent of the American Joint Committee on Cancer eighth edition staging system in patients with cutaneous squamous cell carcinoma treated with multimodality therapy.

Melody J Xu1, Ann A Lazar2, Adam A Garsa1, Sarah T Arron3, William R Ryan4, Ivan H El-Sayed4, Jonathan R George4, Alain P Algazi5, Chase M Heaton4, Patrick K Ha4, Sue S Yom1,4.   

Abstract

BACKGROUND: The purpose of this study was to assess changes resulting from the American Joint Committee on Cancer (AJCC) eighth edition for cutaneous squamous cell carcinoma (SCC) and evaluate pertinent excluded factors.
METHODS: In 101 patients receiving surgery and postoperative radiation, recurrence and survival were estimated by cumulative incidence and Kaplan-Meier method. Time-to-event analysis was performed using Cox proportional hazards and Fine-Gray competing risks regression models.
RESULTS: The 2-year locoregional recurrence, overall survival (OS), and cause-specific mortality rates were 25%, 72%, and 13%, respectively. The AJCC eighth edition upstaged T classification in 50% of patients and overall stage in 39%. In multivariate analysis, immunosuppression and in-transit metastasis were associated with locoregional recurrence. Older age and in-transit metastasis were associated with worse OS. In univariate analysis (limited by number of events), cause-specific mortality was associated with positive margin, in-transit metastasis, and the seventh edition dichotomized T classification and overall stage.
CONCLUSION: In-transit metastasis was significantly associated with locoregional recurrence, OS, and cause-specific mortality. Efforts should be made to define in-transit metastasis in the staging system.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  American Joint Committee on Cancer (AJCC) eighth edition staging; cutaneous squamous cell carcinoma; immunosuppression; in-transit metastasis; postoperative radiotherapy

Mesh:

Year:  2018        PMID: 29524273     DOI: 10.1002/hed.25114

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  5 in total

1.  Treatment and reconstruction of a complicated infected scalp squamous cell carcinoma with CNS invasion.

Authors:  Andreas Nørgaard Glud; Frantz Rom Poulsen; Jane Linnet; Jens Ahm Sørensen
Journal:  BMJ Case Rep       Date:  2018-04-28

2.  Risk of keratinocyte carcinoma among patients with hidradenitis suppurativa.

Authors:  S Ashrafzadeh; Y Kim; G A Peters; H Lee; M M Asgari
Journal:  Br J Dermatol       Date:  2020-07-09       Impact factor: 9.302

3.  Evidence-Based Consensus Recommendations for the Evolving Treatment of Patients with High-Risk and Advanced Cutaneous Squamous Cell Carcinoma.

Authors:  Guilherme Rabinowits; Michael R Migden; Todd E Schlesinger; Robert L Ferris; Morganna Freeman; Valerie Guild; Shlomo Koyfman; Anna C Pavlick; Neil Swanson; Gregory T Wolf; Scott M Dinehart
Journal:  JID Innov       Date:  2021-08-25

4.  Anti-PD-1 for the treatment of advanced cutaneous squamous cell carcinoma in elderly patients: a French multicenter retrospective survey.

Authors:  Quentin Samaran; Romain Samaran; Ernestine Ferreira; Naeda Haddad; Antoine Fottorino; Hervé Maillard; Brigitte Dreno; Nicolas Meyer; David Azria; Eve Maubec; Caroline Gaudy-Marqueste; Nicolas Molinari; Pierre-Emmanuel Stoebner; Olivier Dereure
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-12       Impact factor: 4.322

5.  Institutional Experience of Treatment and Outcomes for Cutaneous Periauricular Squamous Cell Carcinoma.

Authors:  Kevin J Kovatch; Joshua D Smith; Andrew C Birkeland; John E Hanks; Rasha Jawad; Scott A McLean; Alison B Durham; Ashok Srinivasan; Jonathan B McHugh; Gregory J Basura
Journal:  OTO Open       Date:  2019-09-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.